MedTrace Logo

A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"

NCT07382739 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2026-04-14

No results posted yet for this study

Summary

To learn if low doses of radiation therapy can help the drug elranatamab enhance the killing effect of the cancer cells.

Conditions

  • Phase 2
  • Radiotherapy-Induced Immune Priming
  • Elranatamab
  • Relapsed Refractory Multiple Myeloma (RRMM)
  • Extramedullary Disease in Multiple Myeloma
  • Paramedullary Disease
  • PMD

Interventions

DRUG

Elranatamab

Given by IV

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Christine Ye, MD · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-31
Primary Completion
2028-12-31
Completion
2030-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07382739 on ClinicalTrials.gov